725 results on '"Ruff, Christian T"'
Search Results
2. Will Factor XI Inhibitors Replace Current Anticoagulants for Stroke Prevention in Atrial Fibrillation?
3. Genetic drivers of heterogeneity in type 2 diabetes pathophysiology
4. Effects of newer anti-hyperglycemic agents on cardiovascular outcomes in older adults: Systematic review and meta-analysis
5. Response by Aggarwal et al to Letter Regarding Article, “Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants”
6. Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design
7. Endophenotype effect sizes support variant pathogenicity in monogenic disease susceptibility genes
8. When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review
9. Subclinical Atrial Fibrillation and Anticoagulation: Weighing the Absolute Risks and Benefits
10. Efficacy and Safety of Non–Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation
11. Neutrophil-lymphocyte ratio and clinical outcomes in 19,697 patients with atrial fibrillation: Analyses from ENGAGE AF- TIMI 48 trial
12. Abstract 15339: CAD Polygenic Risk Score and Incident Complex Coronary Revascularization in Adults With Atherosclerosis
13. Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants
14. Stroke genetics informs drug discovery and risk prediction across ancestries
15. Risks of Heart Failure, Stroke, and Bleeding in Atrial Fibrillation According to Heart Failure Phenotypes
16. Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroups
17. Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial
18. Publisher Correction: Endophenotype effect sizes support variant pathogenicity in monogenic disease susceptibility genes
19. Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient-Level Meta-Analysis From COMBINE AF.
20. Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation: Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial.
21. Application of the Win Ratio Method in the ENGAGE AF-TIMI 48 Trial Comparing Edoxaban With Warfarin in Patients With Atrial Fibrillation.
22. Novel Polygenic Risk Score and Established Clinical Risk Factors for Risk Estimation of Aortic Stenosis
23. Abstract 13496: Sequencing in Over 50,000 Cases Identifies Coding and Structural Variation Underlying Atrial Fibrillation Risk
24. Abstract 12593: Type 2 Diabetes Mellitus Polygenic Score Predicts New Onset Diabetes in Patients With Established Atherosclerotic Cardiovascular Disease: A FOURIER Sub-Study
25. Abstract 12361: Efficacy and Safety of NOACs vs. Warfarin Across the Continuous Range of Body Mass Index and Body Weight: Insights From COMBINE-AF
26. Abstract 12228: Development of a Novel Polygenic Risk Score to Predict Risk of Aortic Stenosis Events
27. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial
28. Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation
29. Publisher Correction: Stroke genetics informs drug discovery and risk prediction across ancestries
30. Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative
31. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex
32. Tirzepatide for diabetes: on track to SURPASS current therapy
33. Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease
34. LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease
35. Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants
36. Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation: The ENGAGE AF-TIMI 48 Trial
37. Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial
38. The Effect of PCSK9 Inhibition on the Risk of Venous Thromboembolism
39. Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease
40. Per-Particle Cardiovascular Risk of Lipoprotein(a) vs Non-Lp(a) Apolipoprotein B-Containing Lipoproteins
41. Serial assessment of biomarkers and heart failure outcomes in patients with atrial fibrillation
42. Abstract 13702: A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients With Cardiometabolic Disease
43. Abstract 13588: Cardiovascular Outcomes in Patients With Established Atherosclerosis and LDLR Loss of Function: Results From the FOURIER Trial
44. Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF–TIMI 48 Trial
45. Response by Marston et al to Letter Regarding Article, “The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism”
46. The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism
47. Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial
48. Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial
49. GENETIC PREDISPOSITION TO ADIPOSITY IS ASSOCIATED WITH GREATER RISK OF SUBSEQUENT HEART FAILURE EVENTS IN INDIVIDUALS WITH TYPE 2 DIABETES MELLITUS
50. GENETICALLY MEDIATED VASCULAR ENDOTHELIAL CELL DYSFUNCTION AND ITS DEPENDENCE ON SERUM LDL CHOLESTEROL LEVELS FOR THE DEVELOPMENT OF CORONARY ARTERY ATHEROSCLEROSIS: GENETIC INSIGHTS FROM THE UKBB AND FOURIER TRIAL
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.